Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid

Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid

This review presents studies of the association between the use of sodium valproate formulations and increases in body weight in patients with epilepsy, as well as other valproate-induced side effects, including insulin resistance.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience and behavioral physiology 2020, Vol.50 (1), p.13-19
Hauptverfasser: Drokov, A. P., Lipatova, L. V., Shnayder, N. A., Nasyrova, R. F.
Format: Artikel
Sprache:eng
Schlagworte:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Body weight
Epilepsy
Health risk assessment
Insulin
Insulin resistance
Metabolic disorders
Neurobiology
Neurosciences
Sodium valproate
Valproic acid
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This review presents studies of the association between the use of sodium valproate formulations and increases in body weight in patients with epilepsy, as well as other valproate-induced side effects, including insulin resistance.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-019-00861-6